Summary

This KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus.

Questions topics -

  • Current & future use of RTX in lupus
  • Views on RTX’s Phase II/III EXPLORER trial re-analysis
  • Opinion on data demonstrating that RTX is effective for the management of refractory SLE
  • Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination therapy
  • Lupus patients most suitable for RTX + BEL combination therapy
  • Use of RTX + BEL combination therapy




Key Highlights

  • Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price
  • Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high and consequently impeded results
  • Most KOLs flagged that payers may be a barrier to combination therapy use, especially given the lack of approval for RTX in lupus.




Scope

  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our Lupus key opinion leaders (KOLs).



In total, we conducted interviews with 10 KOLs -

  • 5 Europe-based & 5 N. America-based
  • Interviews performed during Q2 2018



KOL data is analyzed to produce -

  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma’s analysts




Reasons To Buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on Rituximab Use in Lupus
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.